SG11201500585XA - 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel - Google Patents
3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channelInfo
- Publication number
- SG11201500585XA SG11201500585XA SG11201500585XA SG11201500585XA SG11201500585XA SG 11201500585X A SG11201500585X A SG 11201500585XA SG 11201500585X A SG11201500585X A SG 11201500585XA SG 11201500585X A SG11201500585X A SG 11201500585XA SG 11201500585X A SG11201500585X A SG 11201500585XA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- potassium channel
- activated potassium
- calcium activated
- oxazolidinone derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12190319 | 2012-10-29 | ||
| PCT/EP2013/072361 WO2014067861A1 (en) | 2012-10-29 | 2013-10-25 | 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201500585XA true SG11201500585XA (en) | 2015-04-29 |
Family
ID=47143594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201500585XA SG11201500585XA (en) | 2012-10-29 | 2013-10-25 | 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9611232B2 (et) |
| EP (1) | EP2912034B1 (et) |
| JP (1) | JP6216385B2 (et) |
| KR (1) | KR20150075091A (et) |
| CN (1) | CN104781256B (et) |
| AR (1) | AR093168A1 (et) |
| AU (1) | AU2013339607A1 (et) |
| BR (1) | BR112015003996A2 (et) |
| CA (1) | CA2879249A1 (et) |
| CL (1) | CL2015000906A1 (et) |
| CO (1) | CO7170170A2 (et) |
| CR (1) | CR20150159A (et) |
| EA (1) | EA026161B1 (et) |
| HK (1) | HK1207632A1 (et) |
| IL (1) | IL237331A0 (et) |
| IN (1) | IN2015DN00961A (et) |
| MA (1) | MA38135B1 (et) |
| MX (1) | MX2015002399A (et) |
| PE (1) | PE20150775A1 (et) |
| PH (1) | PH12015500292A1 (et) |
| SG (1) | SG11201500585XA (et) |
| TW (1) | TW201422596A (et) |
| UA (1) | UA114649C2 (et) |
| WO (1) | WO2014067861A1 (et) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102047502B1 (ko) * | 2016-06-20 | 2019-11-22 | 셀라이온바이오메드 주식회사 | 포타슘 채널 단백질을 이용한 암 진단용 조성물 |
| KR20210143756A (ko) | 2019-03-22 | 2021-11-29 | 사니오나 에이/에스 | 신규의 칼륨 채널 억제제 |
| JP2023544520A (ja) | 2020-09-22 | 2023-10-24 | サニオナ エー／エス | 新規カリウムチャネル阻害剤 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2538424C2 (de) * | 1975-08-29 | 1983-01-05 | Nordmark-Werke Gmbh, 2000 Hamburg | 4-substituierte 5-Phenyl-oxazolidon-(2)- Verbindungen und ein diese enthaltendes pharmazeutisches Präparat |
| JPS63152383A (ja) * | 1985-09-09 | 1988-06-24 | Otsuka Pharmaceut Co Ltd | ２−オキサ−イソセフエム誘導体 |
| CA2095429A1 (en) * | 1990-11-06 | 1992-05-07 | Paul E. Bender | Imidazolidinone compounds |
| DE4439846A1 (de) * | 1994-11-08 | 1996-05-09 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| AU1812197A (en) * | 1996-03-01 | 1997-09-16 | Sankyo Company Limited | Hydroxamic acid derivatives |
| NZ511334A (en) * | 1998-12-04 | 2003-06-30 | Neurosearch As | Benzimidazolone derivatives useful as ion channel modulating agents |
| JP3966693B2 (ja) * | 2000-01-20 | 2007-08-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 含窒素環化合物およびそれらを含んでなる医薬組成物 |
| CN1205185C (zh) * | 2000-01-20 | 2005-06-08 | 卫材株式会社 | 含氮的环状化合物及含有该化合物的药物组合物 |
| EP1339716B1 (de) * | 2000-11-22 | 2004-11-03 | Bayer HealthCare AG | lactam-substituierte pyrazolopyridinderivate |
| JP4719745B2 (ja) | 2004-07-29 | 2011-07-06 | メルク・シャープ・エンド・ドーム・コーポレイション | カリウムチャンネル阻害剤 |
| DE102004060229A1 (de) * | 2004-12-15 | 2006-06-29 | Sanofi-Aventis Deutschland Gmbh | Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen |
| US7378530B2 (en) * | 2005-02-22 | 2008-05-27 | Nereus Pharmaceuticals, Inc. | Anti-cancer and anti-microbial 5-membered heterocyclic compounds |
| US20100056637A1 (en) | 2005-12-20 | 2010-03-04 | Icagen, Inc. | Treatment methods using triaryl methane compounds |
| WO2007109098A2 (en) * | 2006-03-16 | 2007-09-27 | Azevan Pharmaceuticals, Inc. | HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS |
| AR074558A1 (es) | 2008-12-12 | 2011-01-26 | Solvay Pharm Bv | Espiro azepan oxazolidinonas como bloqueadores del canal de potasio kv1.3 |
| WO2010123997A1 (en) * | 2009-04-22 | 2010-10-28 | Achaogen, Inc. | Carbacephem beta-lactam antibiotics |
-
2013
- 2013-10-25 BR BR112015003996A patent/BR112015003996A2/pt not_active IP Right Cessation
- 2013-10-25 PE PE2015000296A patent/PE20150775A1/es not_active Application Discontinuation
- 2013-10-25 CN CN201380056503.4A patent/CN104781256B/zh not_active Expired - Fee Related
- 2013-10-25 MX MX2015002399A patent/MX2015002399A/es unknown
- 2013-10-25 UA UAA201504977A patent/UA114649C2/uk unknown
- 2013-10-25 EA EA201590729A patent/EA026161B1/ru not_active IP Right Cessation
- 2013-10-25 KR KR1020157011024A patent/KR20150075091A/ko not_active Application Discontinuation
- 2013-10-25 AU AU2013339607A patent/AU2013339607A1/en not_active Abandoned
- 2013-10-25 SG SG11201500585XA patent/SG11201500585XA/en unknown
- 2013-10-25 MA MA38135A patent/MA38135B1/fr unknown
- 2013-10-25 WO PCT/EP2013/072361 patent/WO2014067861A1/en active Application Filing
- 2013-10-25 IN IN961DEN2015 patent/IN2015DN00961A/en unknown
- 2013-10-25 JP JP2015538458A patent/JP6216385B2/ja not_active Expired - Fee Related
- 2013-10-25 EP EP13783333.1A patent/EP2912034B1/en not_active Not-in-force
- 2013-10-25 CA CA2879249A patent/CA2879249A1/en not_active Abandoned
- 2013-10-28 TW TW102138950A patent/TW201422596A/zh unknown
- 2013-10-28 AR ARP130103922A patent/AR093168A1/es unknown
-
2015
- 2015-01-16 CO CO15008510A patent/CO7170170A2/es unknown
- 2015-02-10 PH PH12015500292A patent/PH12015500292A1/en unknown
- 2015-02-19 IL IL237331A patent/IL237331A0/en unknown
- 2015-03-20 CR CR20150159A patent/CR20150159A/es unknown
- 2015-04-10 CL CL2015000906A patent/CL2015000906A1/es unknown
- 2015-04-29 US US14/699,144 patent/US9611232B2/en not_active Expired - Fee Related
- 2015-08-25 HK HK15108258.3A patent/HK1207632A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN104781256B (zh) | 2017-09-29 |
| MA38135A2 (fr) | 2016-11-30 |
| CR20150159A (es) | 2015-04-30 |
| IN2015DN00961A (et) | 2015-06-12 |
| IL237331A0 (en) | 2015-04-30 |
| EP2912034B1 (en) | 2017-05-31 |
| CL2015000906A1 (es) | 2015-09-11 |
| MA38135B1 (fr) | 2018-11-30 |
| CO7170170A2 (es) | 2015-01-28 |
| KR20150075091A (ko) | 2015-07-02 |
| EA026161B1 (ru) | 2017-03-31 |
| AU2013339607A1 (en) | 2015-02-05 |
| JP6216385B2 (ja) | 2017-10-18 |
| BR112015003996A2 (pt) | 2017-07-04 |
| WO2014067861A1 (en) | 2014-05-08 |
| AR093168A1 (es) | 2015-05-20 |
| UA114649C2 (uk) | 2017-07-10 |
| CA2879249A1 (en) | 2014-05-08 |
| US9611232B2 (en) | 2017-04-04 |
| EA201590729A1 (ru) | 2015-07-30 |
| TW201422596A (zh) | 2014-06-16 |
| US20150246894A1 (en) | 2015-09-03 |
| PH12015500292A1 (en) | 2015-04-20 |
| PE20150775A1 (es) | 2015-05-21 |
| HK1207632A1 (en) | 2016-02-05 |
| EP2912034A1 (en) | 2015-09-02 |
| JP2015535231A (ja) | 2015-12-10 |
| MX2015002399A (es) | 2015-06-10 |
| CN104781256A (zh) | 2015-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL238876A0 (en) | Indoleamine 2,3-dioxygenase inhibitors, preparations containing them and their uses | |
| IL245184B (en) | Prostacyclin compounds, preparations and methods of using them | |
| HK1215579A1 (zh) | 被取代的 -二氫苯並呋喃基化合物和其用途 | |
| AP2014007835A0 (en) | Oxazolidin-2-one compounds and uses thereof as P13KS inhibitors | |
| IL246252A0 (en) | Diaminopyrimidyl derivative compounds, their compositions and methods of treatment | |
| IL240196B (en) | Amide compounds, preparations containing them and their uses | |
| PT2920149T (pt) | Compostos de 3-aminocicloalquil como inibidores de ror-gama-t e utilizações dos mesmos | |
| IL247469A0 (en) | Methods for refining conjugates based on alpha il-15/il-15r, preparations containing products produced in this way and their uses | |
| PL2431442T3 (pl) | Kompozycja na bazie 1,3,3,3-tetrafluoropropenu | |
| HK1205513A1 (en) | Equatorial-fluorine-substituted neuraminidase inhibitor compounds, compositions and methods for the use thereof as anti-virals | |
| EP2968357A4 (en) | S-IMINO-S-OXO IMINOTHIAZINE COMPOUNDS AS INHIBITORS OF THE SITE SS CLEAVING ENZYME OF THE APP, COMPOSITIONS, AND USE THEREOF | |
| HK1202415A1 (en) | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15- hetre and methods of use thereof dgla15-ohepa/ 15-hetre | |
| HK1198921A1 (en) | Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof dgla15-ohepa / 15-hetre | |
| EP2968356A4 (en) | S-IMINO-S-OXO IMINOTHIADIAZINE COMPOUNDS AS APP-SITE CLEAVING ENZYME INHIBITORS, COMPOSITIONS, AND USE THEREOF | |
| BR112013003536A2 (pt) | composição, e utilização de uma composição. | |
| IL223865A0 (en) | Calcium salts of dihydrooroorotate dehydrogenase inhibitors, compositions comprising the same and uses thereof | |
| IL233529A0 (en) | 1, 5-naphthyridine derivatives and malac inhibitors containing them | |
| SG10201800741QA (en) | BENZO-[d][1,2,3]TRIAZINE COMPOUNDS AND USE AS p70S6K INHIBITORS | |
| MX369290B (es) | Inhibidores de fbx03. | |
| EP3082823A4 (en) | Iminothiadiazepane dioxide compounds as bace inhibitors, compositions, and their use | |
| EP2978761A4 (en) | NOVEL OXAZOLIDINONE DERIVATIVE AS INHIBITOR OF CETP, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | |
| HK1207632A1 (en) | 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel 34- | |
| SG11201601921RA (en) | Azeotrope-like compositions of fo-e-1,3,4,4,4-pentafluoro-3-trifluoromethyl-1-butene and e-1-chloro-3,3,3-trifluoropropene and uses thereof | |
| IL230655A0 (en) | Derivatives n-hetero-converted in the amide ring, preparations containing them and their uses | |
| TWI560186B (en) | Novel compound, phamraceutical composition or combination product comprising the same, and use thereof |